Yu. N. Likar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu. N. Likar has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Denis Y. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
21 shared publications - Tatyana V. Shamanskaya
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian Federation
19 shared publications - Mikhail Ya. Yadgarov
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Ministry of Education and Science of Russia
17 shared publications - E. D. Kireeva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
11 shared publications - Galina V. Tereshchenko
Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
11 shared publications - Kailash
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
9 shared publications
Latest Publications
- 20 October 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (12) , 1104-1106
Unusual Isolated Thymic Relapse of Neuroblastoma Detected By 123I-mIBG Scintigraphy in a Pediatric Patient
Neuroblastoma (NB) is the most common extracranial solid malignancy of childhood, arising from neural crest cells of the sympathetic nervous system. Metastatic spread most frequently involves the bone marrow, bones, lymph nodes, and liver, whereas soft-tissue, central nervous system, and pulmonary metastases are less common. Unusual sites of recurrence may present a significant diagnostic challenge. We report a rare case of thymic relapse of NB presenting as an anterior mediastinal mass with intense uptake on 123 I-meta-iodobenzylguanidine ( 123 I-mIBG) scintigraphy. This case highlights an uncommon pattern of NB recurrence and the value of 123 I-mIBG imaging in its detection.
- 20 October 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (12) , 1104-1106
Unusual Isolated Thymic Relapse of Neuroblastoma Detected By 123I-mIBG Scintigraphy in a Pediatric Patient
Neuroblastoma (NB) is the most common extracranial solid malignancy of childhood, arising from neural crest cells of the sympathetic nervous system. Metastatic spread most frequently involves the bone marrow, bones, lymph nodes, and liver, whereas soft-tissue, central nervous system, and pulmonary metastases are less common. Unusual sites of recurrence may present a significant diagnostic challenge. We report a rare case of thymic relapse of NB presenting as an anterior mediastinal mass with intense uptake on 123 I-meta-iodobenzylguanidine ( 123 I-mIBG) scintigraphy. This case highlights an uncommon pattern of NB recurrence and the value of 123 I-mIBG imaging in its detection.
- 4 September 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Unexpected ¹⁸F-DOPA Uptake in Pediatric Posterior Mediastinal Ewing Sarcoma: A Diagnostic Pitfall in Pediatric Oncology
¹⁸F-DOPA PET/CT is a well-established imaging modality in pediatric nuclear medicine, with applications in both oncologic and nononcologic conditions. Common indications include brain tumors, neuroendocrine neoplasms, neuroblastoma, and congenital hyperinsulinism. Here, we present an unusual case of ¹⁸F-DOPA uptake in Ewing sarcoma. This case illustrates a potential diagnostic pitfall, emphasizing that ¹⁸F-DOPA avidity is not specific for neuroendocrine or neuroblastic tumors and may occur in non-neuroendocrine malignancies.
- 4 September 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Unexpected ¹⁸F-DOPA Uptake in Pediatric Posterior Mediastinal Ewing Sarcoma: A Diagnostic Pitfall in Pediatric Oncology
¹⁸F-DOPA PET/CT is a well-established imaging modality in pediatric nuclear medicine, with applications in both oncologic and nononcologic conditions. Common indications include brain tumors, neuroendocrine neoplasms, neuroblastoma, and congenital hyperinsulinism. Here, we present an unusual case of ¹⁸F-DOPA uptake in Ewing sarcoma. This case illustrates a potential diagnostic pitfall, emphasizing that ¹⁸F-DOPA avidity is not specific for neuroendocrine or neuroblastic tumors and may occur in non-neuroendocrine malignancies.
- Open Access
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 109-121
Treatment of pediatric patients with localized Ewing sarcoma
Introduction. Localized Ewing sarcoma (ES) is a rare aggressive malignant neoplasm coming from small blue round cells, affecting bones and soft tissues, diagnosed most often in adolescents and young adults. ES accounts for 2% of all malignant neoplasms in children and 27% of all primary malignant bone tumors in patients aged 15–29 years. From 2012 to 2024, the musculoskeletal sarcoma research group of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology registered patients in the unified database and coordinated all stages of diagnosis and treatment of children and adolescents with ES in cooperation with regional clinics. Aim: to analyse the effectiveness of treatment in patients with localized form of ES treated according to the EWING 2008 or Euro Ewing 2012 protocols in the Russian Federation. Materials and methods. The prospective study included 193 patients with localized ES, registered by the musculoskeletal sarcoma research group at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between 2012 and 2024. The patients received chemotherapy based on the EWING 2008 protocol and arm B of the Euro Ewing 2012 protocol. Initial patient characteristics, overall (OS) and event-free (EFS) survival were evaluated depending on tumor localization, treatment regimen, extent of surgical resection, pathologic response to treatment. Results. Treatment according to arm B of the Euro Ewing 2012 protocol proved to be more effective than the previously used chemotherapy according to the EWING 2008 protocol (5-year EFS in the Euro Ewing 2012 and EWING 2008 groups: 74.2 ± 5.1% and 68.0 ± 5.2%, respectively (p = 0.5053), 5-year OS in the Euro Ewing 2012 and EWING 2008 groups: 90.1 ± 3.9% and 83.8 ± 4.1%, respectively (p = 0.3257)). Three-year EFS of patients with localized ES who received high-dose chemotherapy exceeded the results of the Euro Ewing study group: 83.6 ± 8.7% versus 69.0% (95% confidence interval 60.2–76.6), respectively. Conclusion. The obtained statistical results of OS and EFS are consistent with global data, but we identified several features characteristic of the Russian population.
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 109-121
Open AccessTreatment of pediatric patients with localized Ewing sarcoma
Introduction. Localized Ewing sarcoma (ES) is a rare aggressive malignant neoplasm coming from small blue round cells, affecting bones and soft tissues, diagnosed most often in adolescents and young adults. ES accounts for 2% of all malignant neoplasms in children and 27% of all primary malignant bone tumors in patients aged 15–29 years. From 2012 to 2024, the musculoskeletal sarcoma research group of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology registered patients in the unified database and coordinated all stages of diagnosis and treatment of children and adolescents with ES in cooperation with regional clinics. Aim: to analyse the effectiveness of treatment in patients with localized form of ES treated according to the EWING 2008 or Euro Ewing 2012 protocols in the Russian Federation. Materials and methods. The prospective study included 193 patients with localized ES, registered by the musculoskeletal sarcoma research group at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between 2012 and 2024. The patients received chemotherapy based on the EWING 2008 protocol and arm B of the Euro Ewing 2012 protocol. Initial patient characteristics, overall (OS) and event-free (EFS) survival were evaluated depending on tumor localization, treatment regimen, extent of surgical resection, pathologic response to treatment. Results. Treatment according to arm B of the Euro Ewing 2012 protocol proved to be more effective than the previously used chemotherapy according to the EWING 2008 protocol (5-year EFS in the Euro Ewing 2012 and EWING 2008 groups: 74.2 ± 5.1% and 68.0 ± 5.2%, respectively (p = 0.5053), 5-year OS in the Euro Ewing 2012 and EWING 2008 groups: 90.1 ± 3.9% and 83.8 ± 4.1%, respectively (p = 0.3257)). Three-year EFS of patients with localized ES who received high-dose chemotherapy exceeded the results of the Euro Ewing study group: 83.6 ± 8.7% versus 69.0% (95% confidence interval 60.2–76.6), respectively. Conclusion. The obtained statistical results of OS and EFS are consistent with global data, but we identified several features characteristic of the Russian population.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 22-38
Results of treatment of patients with posterior mediastinal neuroblastoma in the observation group
Background . Neuroblastoma (NB) with primary tumor located in the posterior mediastinum is a unique subgroup characterized by a higher incidence of life-threatening complications, such as epidural compression (EC) and respiratory failure, yet it is associated with favorable long-term outcomes. Materials and methods . The study included patients with low-risk posterior mediastinal NB treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2012 and September 2024 (152 months). Patients were stratified into risk groups and managed according to the GPOH-NB2004 protocol. We evaluated relapse/progression detection methods, disease characteristics, treatment approaches, and long-term outcomes. Results . The study included 146 patients with NB with primary tumor located in the posterior mediastinum, which is 21.6 % of all patients in the observation (low-risk) group registered in the research database of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The median age at diagnosis was 19.6 months (range 0.5–132.5 months) with a female predominance (male-to-female ratio 1:1.2). Most patients (85/146; 58.2 %) presented with stage 2 disease. 38/146 (26.0 %) patients received chemotherapy due to life threatening symptoms, primarily EC, while 87/146 (59.6 %) patients underwent best surgery in the volume of a macroscopic residual tumor. Relapse/progression occurred in 16.4 % (24/146), predominantly detected during routine follow-up imaging (18/24; 75,0 %), with a median time to relapse of 7.8 months (range 3.0–25.3 months). The majority of relapses/progressions were local (18/24; 75.0 %). In 93 % (14/15) of relapsed/progressed cases analyzed retrospectively, MLPA revealed segmental chromosomal aberrations (median 3 aberrations/ patient; range 0–6). The most frequent alterations included 17q gain (n = 11), 2p gain (n = 8), and deletions in 3p (n = 6), 11q (n = 5), and 4q (n = 4). The 5-year event-free survival in patients with mediastinal NB was 79,1 ± 4,0 %, patients with stage 1 showing the highest survival rates (90 ± 6 %) (p = 0.1932). The 5-year overall survival was 95,0 ± 2,1 %. The cumulative incidence of relapse/progression was 18.7 ± 3.5 %, while treatment-related mortality was 2.8 ± 1.4 % (one death from disease progression; five from therapy toxicity). Conclusions. Mediastinal NB is a prognostically favorable group, with excellent survival rates independent of age or stage. Most patients in the low-risk group achieved favorable outcomes, even after relapse/progression. For the majority of patients in the low-risk group, surgery only is sufficient, and this strategy allows to reduce the risk of mortality from the toxicity of therapy without reducing overall survival. However, chemotherapy remains critical for patients with life-threatening complications, such as EC and respiratory failure, which once again highlighting the challenges in managing this subgroup. Strict adherence to the entire follow-up plan during the period of catamnesis is essential for early relapse detection. The molecular profile of the tumor may predict relapses and treatment response, which underscores the need to integrate molecular diagnostic methods (MLPA) to all patients with NB in the low-risk group into routine diagnostics.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 22-38
Open AccessResults of treatment of patients with posterior mediastinal neuroblastoma in the observation group
Background . Neuroblastoma (NB) with primary tumor located in the posterior mediastinum is a unique subgroup characterized by a higher incidence of life-threatening complications, such as epidural compression (EC) and respiratory failure, yet it is associated with favorable long-term outcomes. Materials and methods . The study included patients with low-risk posterior mediastinal NB treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2012 and September 2024 (152 months). Patients were stratified into risk groups and managed according to the GPOH-NB2004 protocol. We evaluated relapse/progression detection methods, disease characteristics, treatment approaches, and long-term outcomes. Results . The study included 146 patients with NB with primary tumor located in the posterior mediastinum, which is 21.6 % of all patients in the observation (low-risk) group registered in the research database of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The median age at diagnosis was 19.6 months (range 0.5–132.5 months) with a female predominance (male-to-female ratio 1:1.2). Most patients (85/146; 58.2 %) presented with stage 2 disease. 38/146 (26.0 %) patients received chemotherapy due to life threatening symptoms, primarily EC, while 87/146 (59.6 %) patients underwent best surgery in the volume of a macroscopic residual tumor. Relapse/progression occurred in 16.4 % (24/146), predominantly detected during routine follow-up imaging (18/24; 75,0 %), with a median time to relapse of 7.8 months (range 3.0–25.3 months). The majority of relapses/progressions were local (18/24; 75.0 %). In 93 % (14/15) of relapsed/progressed cases analyzed retrospectively, MLPA revealed segmental chromosomal aberrations (median 3 aberrations/ patient; range 0–6). The most frequent alterations included 17q gain (n = 11), 2p gain (n = 8), and deletions in 3p (n = 6), 11q (n = 5), and 4q (n = 4). The 5-year event-free survival in patients with mediastinal NB was 79,1 ± 4,0 %, patients with stage 1 showing the highest survival rates (90 ± 6 %) (p = 0.1932). The 5-year overall survival was 95,0 ± 2,1 %. The cumulative incidence of relapse/progression was 18.7 ± 3.5 %, while treatment-related mortality was 2.8 ± 1.4 % (one death from disease progression; five from therapy toxicity). Conclusions. Mediastinal NB is a prognostically favorable group, with excellent survival rates independent of age or stage. Most patients in the low-risk group achieved favorable outcomes, even after relapse/progression. For the majority of patients in the low-risk group, surgery only is sufficient, and this strategy allows to reduce the risk of mortality from the toxicity of therapy without reducing overall survival. However, chemotherapy remains critical for patients with life-threatening complications, such as EC and respiratory failure, which once again highlighting the challenges in managing this subgroup. Strict adherence to the entire follow-up plan during the period of catamnesis is essential for early relapse detection. The molecular profile of the tumor may predict relapses and treatment response, which underscores the need to integrate molecular diagnostic methods (MLPA) to all patients with NB in the low-risk group into routine diagnostics.
- 2 May 2025
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 13 (3) , 283-301
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent brain tumors: a systematic review and meta-analysis
- 2 May 2025
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 13 (3) , 283-301
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent brain tumors: a systematic review and meta-analysis
- Open Access
- 23 April 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (1) , 27-38
Radiation therapy to metastatic sites among patients with high-risk neuroblastoma in first-line therapy
Relevance. Radiation therapy (RT) is one of the components of multimodal treatment among patients with high-risk neuroblastoma (NB), and in combination with surgical treatment is a mandatory element of local control of the primary tumor. At the same time, RT for metastatic sites persisting after completion of induction therapy is not a standard protocol treatment in primary patients with high-risk NB. The effect of RT on metastatic sites on improving long-term survival and reducing recurrence rates continues to be studied.Aim to the study – to investigate approaches to RT for single metastatic foci persisting after induction therapy among patients with NB highrisk group as part of the consolidation phase of first-line therapy.Materials and methods. The retrospective analysis included 11 patients with high-risk NB who underwent RT for metastatic foci as part of first-line therapy at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia from 01.2012 to 12.2023. Patients received therapy according to the modified protocol GPON-NB2004. The indication for RT was the persistence of a single metastatic site detected by 123I-metaiodobenzylguanidine scintigraphy or computed tomography/magnetic resonance imaging after completion of induction chemotherapy.Results. The median age was 31.9 months (range 9.4–128.6 months). All patients were initially with stage 4 disease (one patient had metastatic focus in the orbit without detection of the primary tumor). MYCN gene amplification was detected in 4/11 (36 %) cases. 10/11 (91 %) patients achieved а partial response after induction therapy. In all cases, only one metastatic focus was irradiated. 2/11 patients received radiation to both the primary tumor and metastatic focus.10/11 patients received RT to metastatic sites localized in skeletal bones, 1/11 – to a distant lymph node. Seven of 11 sites received 21 Gy in 14 fractions. The median follow-up was 40 months (range 13–97 months). Only 1 of 11 patients receiving metastatic site irradiation experienced relapse in an irradiated distant site 24 months later. The 3-year relapse-free survival and overall survival were 54 % and 80 % respectively.Conclusions. RT may be an effective method of local control in oligometastatic disease and in case of persisted single metastatic foci after induction chemotherapy in the treatment of high-risk NB. Additional large studies are needed to confirm the role of RT in improving survival with irradiation of metastatic sites.
- 23 April 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (1) , 27-38
Open AccessRadiation therapy to metastatic sites among patients with high-risk neuroblastoma in first-line therapy
Relevance. Radiation therapy (RT) is one of the components of multimodal treatment among patients with high-risk neuroblastoma (NB), and in combination with surgical treatment is a mandatory element of local control of the primary tumor. At the same time, RT for metastatic sites persisting after completion of induction therapy is not a standard protocol treatment in primary patients with high-risk NB. The effect of RT on metastatic sites on improving long-term survival and reducing recurrence rates continues to be studied.Aim to the study – to investigate approaches to RT for single metastatic foci persisting after induction therapy among patients with NB highrisk group as part of the consolidation phase of first-line therapy.Materials and methods. The retrospective analysis included 11 patients with high-risk NB who underwent RT for metastatic foci as part of first-line therapy at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia from 01.2012 to 12.2023. Patients received therapy according to the modified protocol GPON-NB2004. The indication for RT was the persistence of a single metastatic site detected by 123I-metaiodobenzylguanidine scintigraphy or computed tomography/magnetic resonance imaging after completion of induction chemotherapy.Results. The median age was 31.9 months (range 9.4–128.6 months). All patients were initially with stage 4 disease (one patient had metastatic focus in the orbit without detection of the primary tumor). MYCN gene amplification was detected in 4/11 (36 %) cases. 10/11 (91 %) patients achieved а partial response after induction therapy. In all cases, only one metastatic focus was irradiated. 2/11 patients received radiation to both the primary tumor and metastatic focus.10/11 patients received RT to metastatic sites localized in skeletal bones, 1/11 – to a distant lymph node. Seven of 11 sites received 21 Gy in 14 fractions. The median follow-up was 40 months (range 13–97 months). Only 1 of 11 patients receiving metastatic site irradiation experienced relapse in an irradiated distant site 24 months later. The 3-year relapse-free survival and overall survival were 54 % and 80 % respectively.Conclusions. RT may be an effective method of local control in oligometastatic disease and in case of persisted single metastatic foci after induction chemotherapy in the treatment of high-risk NB. Additional large studies are needed to confirm the role of RT in improving survival with irradiation of metastatic sites.
- 16 December 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis
INPLASY2024120063 Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis Keywords: [18F] FET PET; ped…
- 16 December 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis
INPLASY2024120063 Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis Keywords: [18F] FET PET; ped…
- 13 May 2024
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 12 (6) , 703-715
Prognostic significance of [18F]FDG PET metabolic parameters in osteosarcoma and Ewing’s sarcoma: a systematic review and network meta-analysis
- 13 May 2024
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 12 (6) , 703-715
Prognostic significance of [18F]FDG PET metabolic parameters in osteosarcoma and Ewing’s sarcoma: a systematic review and network meta-analysis
- 8 April 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
[18F]FDG PET metabolic parameters for the prediction of histological response to induction chemotherapy in osteosarcoma and Ewing’s sarcoma: a systematic review and network meta-analysis
INPLASY202440041 [18F]FDG PET metabolic parameters for the prediction of histological response to induction chemotherapy in osteosarcoma and Ewing’s sarcoma: a systematic review and network meta-an…
- 8 April 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
[18F]FDG PET metabolic parameters for the prediction of histological response to induction chemotherapy in osteosarcoma and Ewing’s sarcoma: a systematic review and network meta-analysis
INPLASY202440041 [18F]FDG PET metabolic parameters for the prediction of histological response to induction chemotherapy in osteosarcoma and Ewing’s sarcoma: a systematic review and network meta-an…
- 27 February 2024
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 12 (6) , 683-702
Prognostic significance of [18F]FDG PET metabolic parameters in adults and children with soft-tissue sarcoma: a meta-analysis
- 27 February 2024
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 12 (6) , 683-702
Prognostic significance of [18F]FDG PET metabolic parameters in adults and children with soft-tissue sarcoma: a meta-analysis